REMARKS:

Claims 4, 15, 16 and 17 were rejected under 35 USC 112 for referring to "having symptoms similar to hemangioendothelioma".

As the examiner can see, claim 4 has been amended to state that the transgenic mouse "exhibits hemangioma". Support for this amendment may be found throughout the application as filed, for example, at least in the previous claim 4 which states that hamangioma formation results, page 10, line 20 to page 11, line 3 and page 12, lines 5-16.

Claims 1, 3, 4 and 12-17 were rejected under 35 USC 112, first paragraph.

As the examiner can see, the claims have been amended to state that the SM22α promoter is a 'mouse SM22α promoter' as per the examiner's suggestion.

It is respectfully requested that the examiner reconsider the requirement that the claim be restricted to SEQ ID No. 23. As the examiner can see, the claims have also been amended to state that the calreticulin peptide is a 'mouse' calreticulin peptide that has 'at least 80%' homology to SEQ ID No. 23. As noted by the examiner and as discussed in the application as filed, calreticulin proteins are highly conserved. See for example, page 14, lines 23-24. It is believed that one of skill in the art could, on comparison of the mouse CRT sequence with, for example, the CRT sequence from dog and monkey, determine which amino acid residues are highly conserved and which are more likely to tolerate conserved changes. It is therefore believed that it is a sound prediction that mouse calreticulin peptides having at least 80% homology to SEQ ID No 23 would retain function (as required in claims 1 and 4) in the transgenic mouse of the instant invention.

Claims 15 and 17-19 were rejected under 35 USC 112. As the examiner can see, claim 15 has been cancelled and 'corresponding to' has been deleted from claims 17-19.

Further and more favorable consideration is respectfully requested.

Respectfully submitted

Nasrin Mesaeli

PER: 

Michael R. Williams
Registration 45,333

February 15, 2006
Michael R. Williams

Winnipeg, Manitoba, Canada
Telephone (204) 947-1429 - FAX (204) 942-5723